| 1 |
NCT01639924 |
Recruiting |
Evaluation of People With Gastrointestinal Disease |
- Gastrointestinal Diseases
|
|
Observational |
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluate patients with gastrointestinal disorders.
- During a clinically indicated standard of care test or procedure, allow for donation of extra stool, urine, blood, gastric aspirate or gastrointestinal tissue sample for collection and storage.
- Allow outpatient evaluation and follow-up of patients with a variety of gastrointestinal diseases for the purposes of physician education in the NIDDK accredited gastroenterology training program.
|
999999 |
All |
18 Years and older (Adult, Senior) |
NCT01639924 |
120154
12-DK-0154 |
|
June 18, 2012 |
|
|
July 13, 2012 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 2 |
NCT03019042 |
Recruiting |
Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Mild Gastrointestinal Disorder |
|
- Dietary Supplement: Hou Gu Mi Xi
- Other: placebo
|
Interventional |
Not Applicable |
- Jiangxi University of Traditional Chinese Medicine
- Nanchang Hongdu Hospital of Traditional Chinese Medicine
- Nanchang Hospital of Integrated Traditional Chinese and Western Medicine
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline to 52 weeks in scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale)
- Change from baseline to 2, 4, 8, 26, 78 and 104 weeks in scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale)
- Change from baseline to 8, 26, 78 and 104 weeks in Gastrin-17 (ng/L)
- (and 17 more...)
|
406 |
All |
14 Years to 120 Years (Child, Adult, Senior) |
NCT03019042 |
JXUTCM-EBM-01 |
|
October 11, 2016 |
December 2017 |
December 2019 |
January 12, 2017 |
June 28, 2017 |
|
- Jiangxi University of Traditional Chinese Medicine
Nanchang, Jiangxi, China
|
| 3 |
NCT02567292 |
Not yet recruiting |
Human Milk and Congenital Gastrointestinal Disorders |
- Congenital Gastrointestinal Disorders
|
|
Interventional |
Not Applicable |
- Emory University
- Prolacta Bioscience
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time to full enteral feeding
- Number of days of parenteral nutrition
- Difference in conjugated bilirubin levels
- (and 3 more...)
|
150 |
All |
Child, Adult, Senior |
NCT02567292 |
IRB00080481 |
|
April 23, 2018 |
April 30, 2020 |
April 30, 2021 |
October 2, 2015 |
March 23, 2018 |
|
- Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, United States
|
| 4 |
NCT02689648 |
Recruiting |
Long Term Follow up on Functional Gastrointestinal Disorder (FGID) |
- Functional Gastrointestinal Disorder
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage (%) of patients that fulfill the ROME-III criteria for FGID
- ICD 10-diagnosis following the primary investigation
- Current ICD 10-diagnosis
- Number (n) of visits for the primary investigations
|
400 |
All |
3 Years to 18 Years (Child, Adult) |
NCT02689648 |
LUFT2016 |
LUFT |
February 2016 |
January 2020 |
January 2021 |
February 24, 2016 |
October 26, 2016 |
|
- Umeå University, Department of Clinical Sciences
Umeå, Sweden
|
| 5 |
NCT02865564 |
Recruiting |
Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics |
- Gastrointestinal Diseases
- Colic
|
- Dietary Supplement: Lactobacillus reuteri DSM 17938
- Dietary Supplement: Placebo
- Drug: ampicillin and gentamicin
|
Interventional |
Not Applicable |
- University Medical Centre Ljubljana
- University of Ljubljana
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Other
|
- Functional gastrointestinal dysfunction
- Composition of gut microbiota in infants - 1
- Infants crying duration time
- (and 9 more...)
|
100 |
All |
up to 21 Days (Child) |
NCT02865564 |
UPKLjubljana |
|
November 2016 |
December 2018 |
December 2019 |
August 12, 2016 |
December 8, 2017 |
|
- University Medical Centre Ljubljana
Ljubljana, Slovenia
|
| 6 |
NCT01696734 |
Recruiting |
Treatment Protocol for the Compassionate Use of Domperidone |
- Gastrointestinal Diseases
|
- Drug: Domperidone
- Behavioral: Questionnaires
- Other: Phone Calls
|
Interventional |
Phase 3 |
- M.D. Anderson Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Symptom Control of Chronic Gastrointestinal Disorders
|
200 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01696734 |
2012-0261
NCI-2012-02093 |
|
October 2012 |
October 2019 |
October 2019 |
October 1, 2012 |
October 31, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 7 |
NCT02668679 |
Recruiting |
The Effect of Dream Doctors in Children Undergoing Digestive Endoscopic Procedures |
- Gastrointestinal Diseases
|
- Procedure: Sedation of children during gastroscopy with and without the presence of dream doctor
- Device: evaluation of stress with PPI and GSR
- Biological: blood specimens for stress hormones
- Other: Physiological indices for evaluation of stress
|
Interventional |
Not Applicable |
- HaEmek Medical Center, Israel
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Level of anxiety in children undergoing gastroscopies measured by biological indices (blood pressure)
- Level of anxiety in children undergoing gastroscopies measured by biological indices (pulse)
- Level of anxiety in children undergoing gastroscopies measured by biological indices (saturation)
- (and 4 more...)
|
100 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02668679 |
0068-15-EMC |
|
March 30, 2016 |
May 2018 |
May 2018 |
January 29, 2016 |
March 8, 2018 |
|
- Emek Medical Center
Afula, Israel
|
| 8 |
NCT03390309 |
Not yet recruiting |
Evaluation of A Partially Hydrolyzed in Improving FGIDs Symptoms |
- Functional Gastrointestinal Disorders
|
- Other: Partially Hydrolyzed Formula
- Other: Normal Formula
|
Interventional |
Not Applicable |
- Children's Hospital of Fudan University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of total symptom score of infant feeding & stool pattern questionnaire.
|
488 |
All |
1 Month to 6 Months (Child) |
NCT03390309 |
Fudan-AN 001 |
|
May 5, 2018 |
October 30, 2018 |
April 28, 2019 |
January 4, 2018 |
April 10, 2018 |
|
|
| 9 |
NCT02690376 |
Recruiting |
An Observer Blinded Comparison of MACE and Conventional Upper Gastrointestinal Endoscopy in Upper GI Bleeding |
- Gastrointestinal Diseases
|
- Device: Magnetic Assisted Capsule Endoscopy
|
Interventional |
Not Applicable |
- Sheffield Teaching Hospitals NHS Foundation Trust
- IntroMedic USA Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Diagnostic yield of pathology of MACE compared to gastroscopy.
- Mucosal visualisation of the oesophagus and major areas of the stomach during MACE.
- Determine the number of patients with small bowel bleeding
- (and 3 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02690376 |
STH19107 |
MACE |
March 2016 |
September 2018 |
December 2018 |
February 24, 2016 |
November 24, 2017 |
|
- Royal Hallamshire Hospital
Sheffield, South Yorkshire, United Kingdom - Sheffield Teaching Hospitals FT Trust
Sheffield, South Yorkshire, United Kingdom
|
| 10 |
NCT03408886 |
Recruiting |
Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders |
- Autism Spectrum Disorder
- Gastrointestinal Disorder
|
- Drug: Vancomycin
- Drug: MoviPrep
- Biological: Full Spectrum Microbiota
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Childhood Autism Rating Scale (CARS) from baseline to 10 weeks
- Change in Daily Stool Log (DSL) from baseline to 10 weeks
- Change in Social Responsiveness Scale - 2 from baseline to 10 weeks of treatment
- Change in Aberrant Behavior Checklist from baseline to 10 weeks
|
84 |
All |
18 Years to 60 Years (Adult) |
NCT03408886 |
MTT-Adults-1
Wi1XWH-16-1-0492 |
MTT-ASD |
January 4, 2018 |
October 4, 2020 |
September 1, 2021 |
January 24, 2018 |
January 24, 2018 |
|
- Arizona State University
Tempe, Arizona, United States
|
| 11 |
NCT03383029 |
Recruiting |
iEAT 2.0 Open Trial |
- Gastrointestinal Disorders
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Percent Oral Intake
- Change in Total Oral Grams Consumed During Meal
- Change in Percent Needs Met by Formula or Feeding Tube
- (and 2 more...)
|
40 |
All |
12 Months to 6 Years (Child) |
NCT03383029 |
IRB00099562 |
|
November 29, 2017 |
December 1, 2018 |
December 1, 2018 |
December 26, 2017 |
December 26, 2017 |
|
- Children's Healthcare of Atlanta
Atlanta, Georgia, United States
|
| 12 |
NCT03097731 |
Not yet recruiting |
Epidemiological Screening of IL10RA Mutation Rate in China |
|
|
Observational |
|
- Children's Hospital of Fudan University
|
Other |
- Observational Model: Case-Crossover
- Time Perspective: Prospective
|
- The mutation rate of IL-10RA in chinese
|
10000 |
All |
up to 28 Days (Child) |
NCT03097731 |
20170208 |
|
March 20, 2018 |
December 1, 2018 |
May 1, 2019 |
March 31, 2017 |
January 26, 2018 |
|
- Children's hospital of Fudan university
Shanghai, Shanghai, China
|
| 13 |
NCT03008460 |
Recruiting |
Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy |
|
- Drug: Eziclen®/Izinova®
- Drug: Klean-Prep®
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Other
|
- Blinded overall assessment of preparation efficacy (Cleansing Score) success as determined by the colonoscopist upon completion of the examination, based on a 4-point scale (4 - Excellent, 3 - Good, 2 - Fair, 1 - Poor).
- Number (%) of subjects who need a nasogastric tube to complete preparation
- Time to clear effluent measured as time between first intake of prescription and first clear watery stool, as reported by the subject
- (and 10 more...)
|
250 |
All |
12 Years to 17 Years (Child) |
NCT03008460 |
F-FR-58800-003
2016-002265-60 |
EASYKID |
October 15, 2017 |
September 15, 2018 |
October 15, 2018 |
January 2, 2017 |
January 30, 2018 |
|
- Fakultní nemocnice Královské Vinohrady
Praha, Czechia - Všeobecná fakultní nemocnice v Praze
Praha, Czechia - Université de Picardie Jules Verne
Amiens, France - (and 15 more...)
|
| 14 |
NCT03503162 |
Not yet recruiting
New |
Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System |
- Gastrointestinal Disease
- Colorectal Cancer
|
|
Interventional |
Not Applicable |
- Motus GI Medical Technologies Ltd
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- The rate of adequate cleansing level before and after the use of the Pure-Vu System
|
100 |
All |
22 Years and older (Adult, Senior) |
NCT03503162 |
CL00044 |
|
May 2018 |
April 2019 |
May 2019 |
April 19, 2018 |
April 19, 2018 |
|
|
| 15 |
NCT03493009 |
Not yet recruiting
New |
Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System |
- Gastrointestinal Diseases
- Colorectal Cancer
|
|
Interventional |
Not Applicable |
- Motus GI Medical Technologies Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- rate of adequate cleansing level
|
100 |
All |
22 Years to 75 Years (Adult, Senior) |
NCT03493009 |
CL00042 |
|
May 2018 |
November 2018 |
December 2019 |
April 10, 2018 |
April 10, 2018 |
|
|
| 16 |
NCT03258216 |
Recruiting |
TCM Tongue Diagnosis Indices of UGI Disorders |
- Upper Gastrointestinal Disorders
|
- Diagnostic Test: panendoscopy
- Diagnostic Test: tongue image
|
Observational |
|
- Chang Gung Memorial Hospital
- National Sun Yat-sen University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
- Tongue features
- Panendoscopy report
|
500 |
All |
20 Years and older (Adult, Senior) |
NCT03258216 |
104-4725B |
|
January 1, 2016 |
December 31, 2017 |
December 31, 2017 |
August 23, 2017 |
August 23, 2017 |
|
- Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan
|
| 17 |
NCT03460613 |
Recruiting |
Prevalence of FODMAP Intolerance and JHS in FGID and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention |
- Functional Gastrointestinal Disorders
|
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prevalence of Joint Hypermobility / hypermobile Ehlers-Danlos Syndrome according to the criteria of the "2017 International Classification of the Ehlers-Danlos Syndromes" (hEDS)
- Prevalence of FODMAP intolerance according to nutrient challenge testing (NCT).
- Response to dietary intervention
|
650 |
All |
18 Years to 60 Years (Adult) |
NCT03460613 |
2016-01887 |
PreDiMi |
July 7, 2017 |
June 2019 |
June 2020 |
March 9, 2018 |
March 9, 2018 |
|
- UniversitätsSpital
Zürich, Switzerland
|
| 18 |
NCT02731664 |
Recruiting |
GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans |
- Functional Gastrointestinal Disorders
|
- Biological: GLP-1
- Biological: Intravenous saline
|
Interventional |
Phase 1 |
- Uppsala University
- Karolinska Institutet
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Participant)
- Primary Purpose: Basic Science
|
- Motility index (measure of contraction amplitude x duration; area for mmHg x sec)
- Smooth muscle relaxation induced by GLP-1
- Presence of GLP-1 and GLP-2 receptors in gastric and small bowel tissue
|
12 |
All |
18 Years to 60 Years (Adult) |
NCT02731664 |
PRANDMOTGLP |
GLPMOT |
September 2012 |
October 2016 |
December 2016 |
April 7, 2016 |
August 4, 2016 |
|
- Uppsala University
Uppsala, Uppsala county, Sweden
|
| 19 |
NCT03025152 |
Recruiting |
Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer |
- Gastric Cancer
- Gastrointestinal Disease
|
- Dietary Supplement: Hou Gu Mi Xi
- Other: placebo
|
Interventional |
Not Applicable |
- Jiangxi University of Traditional Chinese Medicine
- The First Affiliated Hospital of Nanchang University
- Second Affiliated Hospital of Nanchang University
- Jiangxi Provincial Cancer Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Changes from baseline to 52 weeks in scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale)
- Changes from baseline to 2, 4, 8, 26, 78 and 104 weeks in scores of Spleen Qi Deficiency Symptoms Grading and Quantifying Scale (Units on a scale)
- Changes from baseline to 2, 4, 8, 26, 78 and 104 weeks in scores of Short Form 36 (SF-36) Physical Component Summary (PCS) (Units on a scale)
- (and 22 more...)
|
130 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03025152 |
JXUTCM-EBM-02 |
|
October 2016 |
August 2018 |
December 2019 |
January 19, 2017 |
January 20, 2017 |
|
- Jiangxi University of Traditional Chinese Medicine
Nanchang, Jiangxi, China
|
| 20 |
NCT02947932 |
Not yet recruiting |
Oral Resveratrol to Prevent Post-ERCP Pancreatitis |
- Pancreatitis, Acute
- Gastrointestinal Disease
|
- Drug: Resveratrol
- Drug: Indomethacin
|
Interventional |
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Post-ERCP Pancreatitis
- Moderate-to-severe Pancreatitis
|
2700 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02947932 |
XJTU1AFCT-2016-007 |
|
December 2016 |
March 2018 |
September 2018 |
October 28, 2016 |
October 28, 2016 |
|
|
| 21 |
NCT03014141 |
Not yet recruiting |
Effect of Oat Bran on Bowel Function and Appetite |
- Gastrointestinal Disorder, Functional
|
- Other: Oat bran (Oatwell 28)
- Other: Maltodextrin
|
Interventional |
Phase 2 |
- DSM Nutritional Products, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Whole gut transit time
- Stool frequency
- Fecal output
- (and 12 more...)
|
34 |
All |
18 Years to 60 Years (Adult) |
NCT03014141 |
2015-12-10-OAT |
OATGUT |
January 2017 |
October 2017 |
December 2017 |
January 9, 2017 |
January 9, 2017 |
|
|
| 22 |
NCT02166125 |
Recruiting |
Endoscopic Sutures For Gastrointestinal Tract Disorders: A Prospective Multicenter Registry |
- Endoscopic Suturing Within the Gastrointestinal Tract
|
|
Observational |
|
- Weill Medical College of Cornell University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Clinical Success
- Safety Outcome
|
100 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02166125 |
1207012584 |
|
May 2013 |
May 26, 2017 |
August 26, 2017 |
June 18, 2014 |
February 20, 2017 |
|
- Ochsner Health Center - Kenner
Kenner, Louisiana, United States - Weill Cornell Medical College
New York, New York, United States - Digestive Health Associates of Texas
Dallas, Texas, United States
|
| 23 |
NCT01804959 |
Recruiting |
Clinical Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease |
|
- Dietary Supplement: Vivomixx probiotics
|
Interventional |
Phase 2 |
- Singapore General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- mean difference between probiotics group versus placebo group in gastrointestinal change score from baseline to day 60 of treatment.
- mean difference between 60 days of probiotics versus 120 days of probiotics in gastrointestinal change score from baseline to day 120 of treatment.
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01804959 |
AL-SScGI |
|
May 2013 |
August 2018 |
August 2018 |
March 5, 2013 |
October 11, 2017 |
|
- Singapore General Hospital
Singapore, Singapore
|
| 24 |
NCT03057171 |
Recruiting |
A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA |
- Helicobacter Pylori Infection
- Gastric Ulcer
- Duodenal Ulcer
- Stomach Cancer
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Expression of THRIL, PACER
|
50 |
All |
19 Years and older (Adult, Senior) |
NCT03057171 |
4-2015-0146 |
|
May 2015 |
April 2020 |
April 2020 |
February 17, 2017 |
March 15, 2018 |
|
- Yonsei university College of Medicine
Seoul, Korea, Republic of
|
| 25 |
NCT02614313 |
Not yet recruiting |
Fructose Breath-testing in Irritable Bowel Syndrome (IBS) |
- Functional Gastrointestinal Disorders
- Irritable Bowel Syndrome
|
- Procedure: Open breath test with fructose
- Procedure: Breath test with sweet placebo (Assugrin)
- Procedure: Breath test with neutral placebo (still water)
- Procedure: Blinded breath test with fructose
|
Interventional |
Not Applicable |
- Brain-Gut Research Group
- New Jersey Medical School
- National University, Singapore
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Fructose intolerance, as percentage of patients
- Between-group comparisons of breath test gas concentrations and symptom indices
- Correlations between breath test gas concentrations, symptom indices and metabolite
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT02614313 |
BGRG FBT-PLA |
|
June 2016 |
December 2016 |
December 2017 |
November 25, 2015 |
May 10, 2016 |
|
- Gastoenterology Group Practice
Bern, Switzerland
|
| 26 |
NCT03440047 |
Recruiting |
Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim |
- Gastro-Intestinal Disorder
|
- Device: Fuji Flim Processor VP-7000, Light Source BL-7000
|
Interventional |
Not Applicable |
- Mayo Clinic
- Fujifilm Medical Systems USA, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Number of subjects whose endoscopic images correlated with final clinical and histological diagnosis
|
500 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03440047 |
17-002101 |
|
August 28, 2017 |
December 14, 2018 |
December 30, 2018 |
February 20, 2018 |
February 20, 2018 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States
|
| 27 |
NCT02514057 |
Not yet recruiting |
Gastrointestinal Symptom Questionnaire Validation |
- Those With and Without Gastrointestinal Disorders
|
|
Observational |
|
- University of East Anglia
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Construct validity measured by Validation of new score
|
210 |
All |
18 Years and older (Adult, Senior) |
NCT02514057 |
150725 |
|
July 2017 |
October 2017 |
December 2017 |
August 3, 2015 |
October 26, 2016 |
|
|
| 28 |
NCT03070665 |
Recruiting |
Blood Pressure During ESD is Related With the Postoperative Bleeding |
- Gastrointestinal Disease
- Gastrointestinal Bleeding
|
|
Interventional |
Not Applicable |
- Shanghai Zhongshan Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Prevention
|
- PostESD bleeding
- Post-ESD perforation
- Hospitalization
- (and 4 more...)
|
296 |
All |
14 Years to 90 Years (Child, Adult, Senior) |
NCT03070665 |
ZS-GI |
|
April 1, 2017 |
October 1, 2018 |
December 31, 2018 |
March 3, 2017 |
April 26, 2017 |
|
- Zhongshan Hospital
Shanghai, SHA, China
|
| 29 |
NCT02719496 |
Recruiting |
Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease |
- Gastrointestinal Disorders in Parkinson's Disease
|
|
Interventional |
Phase 2 |
- Nantes University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- increasing the weekly number of exemptions of 3 in the last week of treatment compared with the reference week (Efficacity)
- quality of evacuations
- Gastrointestinal Symptom Rating Scale (quality of life)
- (and 6 more...)
|
45 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT02719496 |
RC15_0396 |
PHYTOPARK |
April 2016 |
April 2018 |
April 2018 |
March 25, 2016 |
August 8, 2016 |
|
- Tiphaine Rouaud
Nantes, France
|
| 30 |
NCT02974686 |
Not yet recruiting |
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation |
- Kidney Transplant Rejection
- Gastrointestinal Disorder, Functional
|
- Drug: Everolimus
- Drug: Mycophenolic Acid
|
Interventional |
Phase 4 |
- Washington University School of Medicine
- Novartis Pharmaceuticals
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Gastrointestinal Symptom Rating Scale
- Biopsy Proven Acute Rejection
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02974686 |
201603167
CRAD001AUS209T |
|
November 2016 |
December 2018 |
December 2018 |
November 28, 2016 |
November 28, 2016 |
|
|
| 31 |
NCT00267501 |
Recruiting |
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders |
- Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease
- Food Allergy
|
|
Observational |
|
- Children's Hospital Medical Center, Cincinnati
|
Other |
- Time Perspective: Prospective
|
|
5000 |
All |
Child, Adult, Senior |
NCT00267501 |
04-12-8
R01 DK075401 |
|
May 2005 |
January 2050 |
January 2050 |
December 21, 2005 |
November 13, 2015 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 32 |
NCT02567175 |
Available |
Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders |
- Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation
|
|
Expanded Access |
|
- Kristin Fiorino
- Children's Hospital of Philadelphia
|
Other |
|
|
|
All |
12 Years and older (Child, Adult, Senior) |
NCT02567175 |
14-010908 |
|
|
|
|
October 2, 2015 |
November 6, 2017 |
|
- The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 33 |
NCT02442115 |
Recruiting |
Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress |
- Autistic Disorder
- Constipation
- Gastrointestinal Diseases
|
- Other: Treatment of Functional Constipation by
|
Observational |
|
- Children's Hospital Los Angeles
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Reduction in F2-IsoProstanes (IsoPs) oxidative stress biomarker
- Reduction in T-score from Social Responsiveness Scale (SRS-2) (Teacher questionnaire)
|
600 |
All |
5 Years to 17 Years (Child) |
NCT02442115 |
09-00212 |
|
September 2009 |
November 2018 |
November 2018 |
May 13, 2015 |
January 10, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - The Center for Autism & Neurodevelopmental Disorders
Santa Ana, California, United States
|
| 34 |
NCT03150212 |
Recruiting |
Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype |
- Constipation-predominant Irritable Bowel Syndrome
|
- Dietary Supplement: Saccharomyces cerevisiae CNCM I-3856
- Dietary Supplement: Placebo
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Abdominal pain/discomfort score rated with Likert scale (ranging from 0 to 7)
|
456 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03150212 |
2016-A01574-47 |
IBS-GO |
March 20, 2017 |
June 2019 |
June 2019 |
May 12, 2017 |
July 14, 2017 |
|
- General pratices
France, France - Eurofins Optimed
Gieres, France - Créabio Rhône Alpes
Givors, France - (and 2 more...)
|
| 35 |
NCT01522573 |
Recruiting |
T-EUS for Gastrointestinal Disorders: A Multicenter Registry |
- Cholangiocarcinoma
- Pancreatic Cancer
- Bile Duct Cancer
- (and 11 more...)
|
- Procedure: EUS guided ERCP
|
Observational |
|
- Weill Medical College of Cornell University
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Safety
- Efficacy
- Survival duration
|
1000 |
All |
18 Years and older (Adult, Senior) |
NCT01522573 |
1111012016 |
EUSERCPReg |
November 2011 |
December 30, 2018 |
December 30, 2018 |
January 31, 2012 |
February 20, 2017 |
|
- Weill Cornell Medical College
New York, New York, United States - Prof. Dr. Everson L.A. Artifon
São Paulo, Brazil
|
| 36 |
NCT02389998 |
Recruiting |
Efficacy of Open Label Placebo in Children With FGIDs |
- Functional Abdominal Pain
- Functional Dyspepsia
- Irritable Bowel Syndrome
- Functional Gastrointestinal Disorders
|
- Other: Placebo Suspension
- Drug: Hyoscyamine
|
Interventional |
Not Applicable |
- Boston Children’s Hospital
- Nationwide Children's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Satisfactory Relief of Symptoms and Overall Improvement (Patient Reported Outcome Measures)
- Catechol-O-methyl transferase (COMT) measurement
- Change in Results of Functional Disability Inventory (FDI)
- (and 3 more...)
|
80 |
All |
8 Years to 21 Years (Child, Adult) |
NCT02389998 |
P00003158 |
Placebo |
July 2014 |
December 2018 |
December 2018 |
March 17, 2015 |
August 29, 2017 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States
|
| 37 |
NCT03266068 |
Recruiting |
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders |
- Campylobacter Infections
- Irritable Bowel Syndrome
|
- Genetic: DNA Analysis of Blood Sample
- Procedure: Flexible sigmoidoscopy with colonic biopsies
- Procedure: Small bowel and colonic gastrointestinal permeability
- Diagnostic Test: Stool sample analysis
|
Observational |
|
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Colonic geometric center at 24 hours
|
150 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03266068 |
12-006529
K23DK103911
P30DK084567
UL1TR000135 |
|
September 2016 |
June 2019 |
August 2019 |
August 29, 2017 |
August 29, 2017 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
| 38 |
NCT03177044 |
Recruiting |
Behavioural Treatment for Functional Bowel Symptoms in Inflammatory Bowel Disease |
- Inflammatory Bowel Diseases
- Functional Gastrointestinal Disorders
|
- Behavioral: Behavioural treatment
|
Interventional |
Not Applicable |
- St Vincent's Hospital Melbourne
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patient rating of improvement in symptoms
- Change in Personal assessment of Constipation Symptoms (PAC-SYM) score
- Change in St Marks Faecal Incontinence Score
- (and 7 more...)
|
35 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03177044 |
HREC/17/SVHM/92 |
LIBERATE |
June 1, 2017 |
December 31, 2019 |
December 31, 2020 |
June 6, 2017 |
June 6, 2017 |
|
- St Vincent's Hospital
Fitzroy, Victoria, Australia
|
| 39 |
NCT03252743 |
Recruiting |
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study. |
- Functional Gastrointestinal Disorders
- Irritable Bowel Syndrome
- Dyspepsia
- Functional Abdominal Pain
|
- Behavioral: Exposure-based internet-delivered CBT
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Global gastrointestinal symptoms (CSI-24: subscale 7 items on GI-symptoms).
- Pain intensity (Faces Pain rating scale)
- Gastrointestinal symptoms module (PedsQL Gastro)
- (and 3 more...)
|
80 |
All |
8 Years to 17 Years (Child) |
NCT03252743 |
FGID IMP 2017 |
|
September 2017 |
July 2018 |
December 2018 |
August 17, 2017 |
August 29, 2017 |
|
- Department of Clinical Neuroscience, Karolinska Institutet
Stockholm, Sweden
|
| 40 |
NCT02778867 |
Recruiting |
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study |
- Eosinophilic Gastrointestinal Disorders (EGIDs)
- Eosinophilic Esophagitis (EoE)
|
- Other: elimination diet therapy
- Drug: Flovent
|
Interventional |
Phase 2
Phase 3 |
- Children's Hospital Medical Center, Cincinnati
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Allergy and Infectious Diseases (NIAID)
- (and 2 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants in histologic remission (defined as < 15 eosinophils per high power field) following a six week randomized trial of one of two empiric diets (1FED or 6FED)
- Number of participants in histologic remission (defined as < 15 eosinophils per high power field) following 6 weeks of swallowed glucocorticoid therapy in the 6FED diet non-responders (Phase 2).
|
136 |
All |
18 Years to 60 Years (Adult) |
NCT02778867 |
2015-1949 |
SOFEED |
November 2015 |
July 2019 |
July 2020 |
May 20, 2016 |
January 29, 2018 |
|
- University of California, San Diego
La Jolla, California, United States - Northwestern University
Chicago, Illinois, United States - Tufts University
Boston, Massachusetts, United States - (and 3 more...)
|
| 41 |
NCT02523118 |
Recruiting |
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages |
- Eosinophilic Gastrointestinal Disorders (EGIDs)
- Eosinophilic Esophagitis
- Eosinophilic Gastritis
- Eosinophilic Colitis
|
|
Observational |
|
- Children's Hospital Medical Center, Cincinnati
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- (and 2 more...)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Other
|
- Mucosal eosinophilia (eos/hpf)
|
1050 |
All |
3 Years to 65 Years (Child, Adult) |
NCT02523118 |
2015-2311
U54AI117870 |
OMEGA |
July 2015 |
December 2050 |
January 2051 |
August 14, 2015 |
January 23, 2017 |
|
- University of California, San Diego
La Jolla, California, United States - Children's Hospital Colorado
Denver, Colorado, United States - Northwestern University
Chicago, Illinois, United States - (and 8 more...)
|
| 42 |
NCT02610816 |
Recruiting |
Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids |
- Eosinophilic Esophagitis
- Eosinophilic Gastrointestinal Disorders (EGIDs),
|
- Other: elimination diet therapy
- Drug: Flovent (fluticasone propionate)
|
Interventional |
Phase 2
Phase 3 |
- Children's Hospital Medical Center, Cincinnati
- Patient-Centered Outcomes Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Pediatric EoE Symptom Score (PEESS, version 2) from pre-treatment to post-treatment.
- Rate of histologic remission following 1FED or 4FED therapy (Phase 1).
- Rate of remission following swallowed glucocorticoid therapy in the 4FED diet non-responders (Phase 2).
|
292 |
All |
6 Years to 17 Years (Child) |
NCT02610816 |
2015-2187 |
|
January 2016 |
November 2017 |
April 2018 |
November 20, 2015 |
June 8, 2016 |
|
- Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
|
| 43 |
NCT03426826 |
Not yet recruiting |
The Gut-Brain Study |
- Autism Spectrum Disorder (ASD)
- Gastro-Intestinal Disorder
|
- Biological: FMT versus placebo
|
Interventional |
Phase 1 |
- Children's Hospital Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Primary Outcome Measures, safety and tolerability
- Secondary Outcome Measures, symptom improvement
|
10 |
All |
5 Years to 17 Years (Child) |
NCT03426826 |
APP-18-00409 |
|
March 2018 |
March 2022 |
June 2022 |
February 8, 2018 |
February 13, 2018 |
|
- Children's Hospital Los Angles
Los Angeles, California, United States
|
| 44 |
NCT03482830 |
Recruiting
New |
Perioperative Metabolic and Hormonal Aspects in Major Emergency Surgery |
- Surgery--Complications
- Acute Illness
- Gastrointestinal Disease
- Stress
|
- Procedure: Major emergency gastrointestinal surgery
|
Observational |
|
- Zealand University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Changes of immunological biomarkers
- Number of patients with stress induced hyperglycemia
- Changes of plasma thyroid hormones
- (and 11 more...)
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT03482830 |
PHASE |
PHASE |
March 5, 2018 |
August 2018 |
February 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Department of Surgery, Zealand University Hospital
Køge, Denmark
|
| 45 |
NCT00910104 |
Recruiting |
Cholestasis Reversal: Efficacy of IV Fish Oil |
- Parenteral Nutrition Associated Liver Disease
- Short Bowel Syndrome
- Gastrointestinal Disease
|
|
Interventional |
Phase 2
Phase 3 |
- Mark Puder
- Boston Children’s Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy of parenteral administration of fish oil derived fat emulsion (Omegaven®) to reverse established parenteral nutrition associated liver disease
|
330 |
All |
up to 17 Years (Child) |
NCT00910104 |
05-04-048
1R01FD003460-02 |
Reversal |
September 2004 |
September 2020 |
September 2020 |
May 29, 2009 |
March 15, 2018 |
|
- Children's Hospital Boston
Boston, Massachusetts, United States
|
| 46 |
NCT03100487 |
Recruiting |
Efficacy of Audio Recorded Guided Imagery vs Deep Breathing Exercises on Functional Gastrointestinal Pain Disorders |
- Abdominal Pain
- Functional Gastrointestinal Disorders
|
- Device: Apple iPod Shuffle
|
Interventional |
Not Applicable |
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in abdominal pain symptoms
- Improvement in health-related quality of life
- Change in Psychosocial Distress
- Adherence to Intervention
|
58 |
All |
8 Years to 12 Years (Child) |
NCT03100487 |
H-39390 (Imagery) |
|
August 2016 |
August 2018 |
August 2019 |
April 4, 2017 |
April 4, 2017 |
|
- Texas Children's Hospital
Houston, Texas, United States
|
| 47 |
NCT03011255 |
Recruiting |
Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer |
- Esophageal Neoplasms
- Esophageal Diseases
- Digestive System Diseases
|
- Biological: peptide specific CTL
|
Interventional |
Phase 2 |
- Shixiu Wu
- Hangzhou Cancer Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Local control
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Objective response rate as assessed by RECIST criteria
- (and 2 more...)
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03011255 |
HangzhouCH06 |
|
December 2016 |
August 2017 |
December 2019 |
January 5, 2017 |
August 7, 2017 |
|
- Hangzhou Cancer Hospital
Hangzhou, Zhejiang, China
|
| 48 |
NCT03011151 |
Recruiting |
Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness |
- Gastroparesis
- Gastrointestinal Disorder, Functional
- Critical Illness
|
|
Observational |
|
- Boston Children’s Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- PAR2 agonist activity- serum zonulin
- PAR2 agonist activity- fecal protease activity
- Gastric motility by the acetaminophen absorption test- AUC
- (and 3 more...)
|
80 |
All |
2 Years to 30 Years (Child, Adult) |
NCT03011151 |
IRB-P00024070 |
|
June 19, 2017 |
December 2018 |
December 2018 |
January 5, 2017 |
June 20, 2017 |
|
- Boston Children's Hospital
Boston, Massachusetts, United States
|
| 49 |
NCT03266315 |
Not yet recruiting |
Probiotics Supplementation and Length of Hospital Stay in Neonates With Gastrointestinal Surgery |
- Probiotics
- Infant, Newborn
- Surgical Procedures, Operative
- Gastro-Intestinal Disorder
|
- Biological: FloraBaby
- Other: Placebo
|
Interventional |
Not Applicable |
- University of Calgary
- University of Alberta
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Duration of hospital stay
- Diversity and abundancy of stool microbiome at baseline and after 1 and 3 weeks of initiation of probiotics
- Time to reach full feed (defined as 120 ml/kg/day) in the post-operative period
- (and 5 more...)
|
88 |
All |
Child, Adult, Senior |
NCT03266315 |
REB16-2401 |
ProPS |
October 2017 |
June 2019 |
August 2019 |
August 30, 2017 |
August 30, 2017 |
|
- University of Calgary
Calgary, Alberta, Canada
|
| 50 |
NCT02855151 |
Recruiting |
EUS for Gastrointestinal Disorders: a Registry |
- GI Tract Disorders
- Pancreatic Disorders
- EUS
|
|
Observational |
|
- Istituto Clinico Humanitas
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Number of participants with treatment-related adverse events
- Diagnostic yied of elastography during EUS
- Diagnostic yied of Contrast-Enhanced Endoscopic Ultrasonography
- Tissue acquisition during EUS
|
10000 |
All |
18 Years and older (Adult, Senior) |
NCT02855151 |
Studio 1494 |
|
January 2013 |
December 2022 |
December 2022 |
August 4, 2016 |
August 4, 2016 |
|
- Endoscopy Unit, Humanitas Research Hospital
Rozzano, Milano, Italy
|
Create an RSS feed from your search for:
Download the search results for: